Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Moderna (MRNA) closed at $58.39 in the latest trading session, marking a -0.56% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Elsewhere, the Dow saw an ...

The rise in mRNA pharmaceuticals’ licensing agreement values suggests that this field will remain a major area for innovation ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

Researchers have been working on mRNA flu vaccines since before the Covid-19 pandemic, but we may get one for bird flu first.

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

Penn Engineers have discovered a simple and inexpensive means of directing lipid nanoparticles (LNPs), the revolutionary ...

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Moderna, Inc. (NASDAQ: MRNA) ...

The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health ...

During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, ...